GILD submits NDA for TAF/Emtiva/Edurant FDC*, using priority-review voucher: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2064274 See #msg-109435833 for info on the two GILD-JNJ collaborations in HIV. *GILD refers to this FDC as “R/F/TAF.”